Trial Profile
A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary)
- Indications Cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 26 Sep 2008 New trial record.